Ergonomic Risk in Head and Neck Surgery

• by Andrea Surnit

• May 6, 2026

Editorial: Biomarkers in head and neck cancer: genomic insights and nuclear medicine innovations

• by Sujith Baliga, Priyanka Bhateja

• May 25, 2026

Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer

• by Harold Nathan Tan, Bettzy Stephen, Oriol Mirallas, Mohamed H. Derbala, Israa Salih, Lilibeth Castillo, Yali Yang, Hung Le, Lei Kang, Heather Lin, Joann Lim, Ecaterina E. Dumbrava, Timothy A. Yap, Jordi Rodón, Sarina A. Piha-Paul, Siqing Fu, Stéphane Champiat, Neal Akhave, Renata Ferrarotto, David S. Hong, Funda Meric-Bernstam, Faye Johnson, Aung Naing

• July 16, 2026

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

• by Kathryn Wighton

• June 15, 2026

• 3 min